Xiaobin Wu sold $15M of ONC
President, COO & GM China at BeOne Medicines Ltd.. 51,921 shares at an average of $281.40, traded Apr 1, 2025, filed Apr 3, 2025.
Score components
- +20RolePresident
- +25Trade size$14.6M at market
- +20Share of holdings soldSold 100% of holdings
- +8Cluster2 insiders selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001651308-25-000053, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Apr 1, 2025 | MOption exercise American Depositary Shares10b5-1 | +16,477 | $119.96 | $2.0M | 16,477 | Apr 3, 2025 |
| Apr 1, 2025 | MOption exercise American Depositary Shares10b5-1 | +35,444 | $174.43 | $6.2M | 51,921 | Apr 3, 2025 |
| Apr 1, 2025 | SOpen-market sale American Depositary Shares10b5-1 | -28,253 | $280.31 | $7.9M | 23,668 | Apr 3, 2025 |
| Apr 1, 2025 | SOpen-market sale American Depositary Shares10b5-1 | -6,364 | $281.67 | $1.8M | 17,304 | Apr 3, 2025 |
| Apr 1, 2025 | SOpen-market sale American Depositary Shares10b5-1 | -12,221 | $282.76 | $3.5M | 5,083 | Apr 3, 2025 |
| Apr 1, 2025 | SOpen-market sale American Depositary Shares10b5-1 | -5,083 | $283.79 | $1.4M | 0 | Apr 3, 2025 |
| Apr 1, 2025 | MOption exercise Share Option (Right to Buy)derivative10b5-1 | -214,201 | $0.00 | $0 | 0 | Apr 3, 2025 |
| Apr 1, 2025 | MOption exercise Share Option (Right to Buy)derivative10b5-1 | -460,772 | $0.00 | $0 | 296,049 | Apr 3, 2025 |
Related signals
Other insiders at BeOne Medicines Ltd. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 39Weak | BeOne Medicines Ltd. | Chan Henry Lee SVP, General Counsel | $418k 1,115 shares | -100% | |
| 33Weak | BeOne Medicines Ltd. | Xiaodong Wang director, other | $11M 31,028 shares | -100% | |
| 33Weak | BeOne Medicines Ltd. | Xiaodong Wang director, other | $13M 38,287 shares | -527% | |
| 49Moderate | BeOne Medicines Ltd. | Titus B. Ball Principal Accounting Officer | $47k 132 shares | -100% | |
| 58Moderate | BeOne Medicines Ltd. | John Oyler Chief Executive Officer | $31M 100,000 shares | -100% | |
| 27Weak | BeOne Medicines Ltd. | Chan Henry Lee SVP, General Counsel | $214k 664 shares | -200% | |
| 69Notable | BeOne Medicines Ltd. | Corazon (Corsee) D. Sanders director | $896k 2,627 shares | -100% | |
| 80Strong | BeOne Medicines Ltd. | Xiaobin Wu President and COO | $1.5M 3,991 shares | -100% | |
| 80Strong | BeOne Medicines Ltd. | Xiaobin Wu President and COO | $5.8M 16,009 shares | -100% | |
| 30Weak | BeOne Medicines Ltd. | Chan Henry Lee SVP, General Counsel | $348k 996 shares | -100% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.